These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8260896)

  • 21. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience.
    Smith BD; Jones RJ; Lee SM; Piantadosi S; Vala MS; Fuller D; Gore SD; Noga SJ; O'Donnell PV; Braine H; Vogelsang GB; Fuchs EJ; Flinn IW; Brodsky RA; Ambinder RF; Miller CB
    Br J Haematol; 2002 Jun; 117(4):907-13. PubMed ID: 12060130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporine-induced encephalopathy in a patient with relapsed acute myeloid leukemia treated with unrelated allogeneic bone marrow transplantation.
    Chen YC; Chao TY; Chen CY; Ho CL
    J Formos Med Assoc; 2000 Mar; 99(3):248-51. PubMed ID: 10820959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New conditioning regimens for high risk marrow transplants.
    Jones RJ; Santos GW
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():15-7. PubMed ID: 2627618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer.
    Kennedy MJ; Vogelsang GB; Beveridge RA; Farmer ER; Altomonte V; Huelskamp AM; Davidson NE
    J Clin Oncol; 1993 Mar; 11(3):478-84. PubMed ID: 8445424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission.
    Lenarsky C; Weinberg K; Petersen J; Nolta J; Brooks J; Annett G; Kohn D; Parkman R
    Bone Marrow Transplant; 1990 Dec; 6(6):425-9. PubMed ID: 2097012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
    De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
    Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow.
    Ball ED; Mills LE; Cornwell GG; Davis BH; Coughlin CT; Howell AL; Stukel TA; Dain BJ; McMillan R; Spruce W
    Blood; 1990 Mar; 75(5):1199-206. PubMed ID: 2306522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation.
    Shaw PJ; Bergin ME; Burgess MA; Dalla Pozza L; Kellie SJ; Rowell G; Stevens MM; Webster BH; Bradstock KF
    J Clin Oncol; 1994 Oct; 12(10):2138-45. PubMed ID: 7931485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation.
    Bolwell B; Sobecks R; Pohlman B; Andresen S; Rybicki L; Kuczkowski E; Kalaycio M
    Bone Marrow Transplant; 2004 Oct; 34(7):621-5. PubMed ID: 15300236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up.
    Ball ED; Wilson J; Phelps V; Neudorf S
    Bone Marrow Transplant; 2000 Apr; 25(8):823-9. PubMed ID: 10808202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
    Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
    Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.
    Singhal S; Powles R; Kulkarni S; Treleaven J; Saso R; Mehta J
    Leuk Lymphoma; 1999 Feb; 32(5-6):505-12. PubMed ID: 10048423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
    Baron F; Gothot A; Salmon JP; Hermanne JP; Pierard GE; Fillet G; Beguin Y
    Br J Haematol; 2000 Dec; 111(3):745-53. PubMed ID: 11122133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cyclosporine-induced graft-versus-host disease in a syngeneic bone marrow transplantation].
    Hashimoto S; Kawano E; Hirasawa A; Morio S; Aotuka N; Nakamura H; Oh H; Asai T; Yoshida S; Ishii G
    Rinsho Ketsueki; 1993 Jan; 34(1):34-8. PubMed ID: 8450605
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
    Linker CA; Damon LE; Ries CA; Rugo HS; Wolf JL
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.